Empowering Lung Cancer Research Through New Award Program

LUNGevity Foundation Launches Innovative Research Award

The LUNGevity Foundation is excited to announce its inaugural Mid-Career "Bridge to Breathe" Research Award, aimed at supporting and retaining mid-career researchers in the field of lung cancer. This initiative highlights the foundation's commitment to promoting ongoing research and ensuring that talented individuals remain active in this critical area of oncology.

The Need for Mid-Career Support in Research

Research data reveals a concerning trend: many mid-career researchers, particularly in the realm of cancer studies, struggle to secure funding after their initial grant. Statistics indicate that nearly 45% of cancer researchers do not succeed in obtaining subsequent funding six years post their first major research grant. This funding gap not only hinders their professional growth but also leads to a drastic reduction in experienced researchers dedicated to lung cancer.

Details on the 'Bridge to Breathe' Award

The newly established LUNGevity Foundation 2025 Mid-Career "Bridge to Breathe" Research Award is specifically designed for researchers between 5 to 15 years into their faculty careers. The awarded funding, which totals up to $150,000 over two years, aims to advance essential research focused on early detection and individualized treatments for lung cancer.

Application Process and Timeline

To apply, candidates must start by submitting a letter of intent (LOI), which is due soon. Following this initial stage, selected applicants will be invited to submit a comprehensive application by the specified deadline. This two-step process ensures that the most promising research proposals receive support.

Impacts of the Award

This award provides a crucial lifeline for talented researchers, encouraging them to continue their vital work in the field. By investing in mid-career professionals, LUNGevity aims to promote innovation and growth, ultimately leading to better outcomes for patients living with lung cancer.

Mission and Vision of LUNGevity Foundation

LUNGevity Foundation holds a prominent position as a leading organization focused on lung cancer. The organization's mission is to improve the quality of life for lung cancer patients and survivors while striving for health equity across the healthcare system.

Research Commitment

Through innovative research efforts, LUNGevity emphasizes the importance of early detection and the development of new treatment methods. The foundation's efforts contribute to a robust pipeline of new investigators who will shape the future of lung cancer research.

Advocacy and Community Engagement

By advocating for increased access to screening and treatment, LUNGevity facilitates collaborations that can revolutionize patient care. In addition, they offer education and support to those affected by lung cancer, ensuring that individuals have access to the resources they need.

About Lung Cancer in the United States

Lung cancer remains a critical health concern, with about 1 in 18 Americans being diagnosed during their lifetime. Despite the increasing number of diagnoses, many patients are still unaware of their heightened risks, especially given that an estimated 65% of new diagnoses occur in individuals with no significant tobacco exposure.

Statistics and Survival Rates

The disease takes more lives than the next two most deadly cancers combined. However, early detection significantly improves survival rates, highlighting the need for continued research and innovative treatment modalities.

Frequently Asked Questions

What is the 'Bridge to Breathe' Research Award?

The award is a new initiative by LUNGevity Foundation aimed at supporting mid-career researchers in lung cancer research.

Who can apply for this award?

Mid-career researchers within 5 to 15 years of their first faculty appointment are eligible to apply.

How much funding will be awarded?

A maximum funding of $150,000 is available over a two-year period for selected research projects.

When is the application deadline?

The letter of intent (LOI) is due on February 14, 2025, and full applications are due by May 12, 2025.

What are the goals of the research projects?

Research projects should aim to create methods for early detection and personalized treatment for lung cancer, with high-risk proposals encouraged.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.